{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:23:41Z","timestamp":1775478221242,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010428","name":"Innovation and Technology Fund","doi-asserted-by":"publisher","award":["GHP\/065\/21SZ"],"award-info":[{"award-number":["GHP\/065\/21SZ"]}],"id":[{"id":"10.13039\/501100010428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Comput Sci"],"DOI":"10.1038\/s43588-025-00887-6","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:04:40Z","timestamp":1759482280000},"page":"39-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predicting drug responses of unseen cell types through transfer learning with foundation models"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8989-3129","authenticated-orcid":false,"given":"Yixuan","family":"Wang","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1303-6921","authenticated-orcid":false,"given":"Xinyuan","family":"Liu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6514-5588","authenticated-orcid":false,"given":"Yimin","family":"Fan","sequence":"additional","affiliation":[]},{"given":"Binghui","family":"Xie","sequence":"additional","affiliation":[]},{"given":"James","family":"Cheng","sequence":"additional","affiliation":[]},{"given":"Kam Chung","family":"Wong","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8474-2906","authenticated-orcid":false,"given":"Peter","family":"Cheung","sequence":"additional","affiliation":[]},{"given":"Irwin","family":"King","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-6722","authenticated-orcid":false,"given":"Yu","family":"Li","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"887_CR1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41573-023-00688-4","volume":"22","author":"B Van de Sande","year":"2023","unstructured":"Van de Sande, B. et al. Applications of single-cell RNA sequencing in drug discovery and development. Nat. Rev. Drug Discov. 22, 496\u2013520 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"887_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.aax6234","volume":"367","author":"SR Srivatsan","year":"2020","unstructured":"Srivatsan, S. R. et al. Massively multiplex chemical transcriptomics at single-cell resolution. Science 367, 45\u201351 (2020).","journal-title":"Science"},{"key":"887_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43929-1","volume":"14","author":"C Zang","year":"2023","unstructured":"Zang, C. et al. High-throughput target trial emulation for Alzheimer\u2019s disease drug repurposing with real-world data. Nat. Commun. 14, 8180 (2023).","journal-title":"Nat. Commun."},{"key":"887_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21330-0","volume":"12","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez, S. et al. Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. Nat. Commun. 12, 1033 (2021).","journal-title":"Nat. Commun."},{"key":"887_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35157-w","volume":"13","author":"Marie-Laure Charpignon","year":"2022","unstructured":"Charpignon, Marie-Laure et al. Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. Nat. Commun. 13, 7652 (2022).","journal-title":"Nat. Commun."},{"key":"887_CR6","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.3390\/cells11142246","volume":"11","author":"H Elhasasna","year":"2022","unstructured":"Elhasasna, H. et al. A drug repurposing screen identifies fludarabine phosphate as a potential therapeutic agent for N-MYC overexpressing neuroendocrine prostate cancers. Cells 11, 2246 (2022).","journal-title":"Cells"},{"key":"887_CR7","doi-asserted-by":"crossref","unstructured":"Yu, M. et al. Deep learning large-scale drug discovery and repurposing. Nat. Comput. Sci. 4, 600\u2013614 (2024).","DOI":"10.1038\/s43588-024-00679-4"},{"key":"887_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom, S. et al. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 18, 41\u201358 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"887_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.aan6828","volume":"358","author":"MichaelJT Stubbington","year":"2017","unstructured":"Stubbington, MichaelJ. T., Rozenblatt-Rosen, O., Regev, A. & Teichmann, S. A. Single-cell transcriptomics to explore the immune system in health and disease. Science 358, 58\u201363 (2017).","journal-title":"Science"},{"key":"887_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nri.2017.76","volume":"18","author":"E Papalexi","year":"2018","unstructured":"Papalexi, E. & Satija, R. Single-cell rna sequencing to explore immune cell heterogeneity. Nat. Rev. Immunol. 18, 35\u201345 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"887_CR11","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1126\/science.aax4438","volume":"365","author":"TM Norman","year":"2019","unstructured":"Norman, T. M. et al. Exploring genetic interaction manifolds constructed from rich single-cell phenotypes. Science 365, 786\u2013793 (2019).","journal-title":"Science"},{"key":"887_CR12","doi-asserted-by":"crossref","unstructured":"Replogle, J. M. et al. Mapping information-rich genotype-phenotype landscapes with genome-scale perturb-SEQ. Cell 185, 2559\u20132575 (2022).","DOI":"10.1016\/j.cell.2022.05.013"},{"key":"887_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrg.2017.97","volume":"19","author":"JG Doench","year":"2018","unstructured":"Doench, J. G. Am i ready for CRISPR? A user\u2019s guide to genetic screens. Nat. Rev. Genet. 19, 67\u201380 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"887_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","volume":"23","author":"M Nakamura","year":"2021","unstructured":"Nakamura, M., Gao, Y., Dominguez, A. A. & Qi, L. S. CRISPR technologies for precise epigenome editing. Nat. Cell Biol. 23, 11\u201322 (2021).","journal-title":"Nat. Cell Biol."},{"key":"887_CR15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/s41587-020-0490-7","volume":"38","author":"RE Hanna","year":"2020","unstructured":"Hanna, R. E. & Doench, J. G. Design and analysis of crispr\u2013cas experiments. Nat. Biotechnol. 38, 813\u2013823 (2020).","journal-title":"Nat. Biotechnol."},{"key":"887_CR16","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1111\/jcmm.12930","volume":"20","author":"B He","year":"2016","unstructured":"He, B. et al. Combination therapeutics in complex diseases. J. Cell. Mol. Medicine 20, 2231\u20132240 (2016).","journal-title":"J. Cell. Mol. Medicine"},{"key":"887_CR17","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s41588-022-01187-9","volume":"54","author":"KA Jagadeesh","year":"2022","unstructured":"Jagadeesh, K. A. et al. Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics. Nat. Genet. 54, 1479\u20131492 (2022).","journal-title":"Nat. Genet."},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41592-019-0494-8","volume":"16","author":"M Lotfollahi","year":"2019","unstructured":"Lotfollahi, M., Wolf, F. A. & Theis, F. J. scGen predicts single-cell perturbation responses. Nat. Methods 16, 715\u2013721 (2019).","journal-title":"Nat. Methods"},{"key":"887_CR19","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41592-023-01969-x","volume":"20","author":"C Bunne","year":"2023","unstructured":"Bunne, C. et al. Learning single-cell perturbation responses using neural optimal transport. Nat. Methods 20, 1759\u20131768 (2023).","journal-title":"Nat. Methods"},{"key":"887_CR20","doi-asserted-by":"crossref","unstructured":"Piran, Z., Cohen, N., Hoshen, Y. & Nitzan, M. Disentanglement of single-cell data with biolord. Nat. Biotechnol. 42, 1678\u20131683 (2024).","DOI":"10.1038\/s41587-023-02079-x"},{"key":"887_CR21","unstructured":"Hetzel, L. et al. Predicting cellular responses to novel drug perturbations at a single-cell resolution. In Proc. 36th International Conference on Neural Information Processing System Vol. 35, 26711\u201326722 (2022)."},{"key":"887_CR22","unstructured":"Lotfollahi, M. et al. Predicting cellular responses to complex perturbations in high-throughput screens. Mol. Syst. Biol. e11517 (2023)."},{"key":"887_CR23","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06139-9","volume":"618","author":"CV Theodoris","year":"2023","unstructured":"Theodoris, C. V. et al. Transfer learning enables predictions in network biology. Nature 618, 616\u2013624 (2023).","journal-title":"Nature"},{"key":"887_CR24","doi-asserted-by":"crossref","unstructured":"Cui, H. et al. scGPT: toward building a foundation model for single-cell multi-omics using generative AI. Nat. Methods 21, 1470\u20131480 (2024).","DOI":"10.1038\/s41592-024-02201-0"},{"key":"887_CR25","doi-asserted-by":"crossref","unstructured":"Hao, M. et al. Large-scale foundation model on single-cell transcriptomics. Nat. Methods 21, 1481\u20131491 (2024).","DOI":"10.1038\/s41592-024-02305-7"},{"key":"887_CR26","doi-asserted-by":"crossref","unstructured":"Heimberg, G. et al. A cell atlas foundation model for scalable search of similar human cells. Nature 638, 1085\u20131094 (2025).","DOI":"10.1038\/s41586-024-08411-y"},{"key":"887_CR27","unstructured":"Neurips 2023: Single-cell Perturbation Prediction (NeurIPS, 2023); https:\/\/www.kaggle.com\/competitions\/open-problems-single-cell-perturbations\/data"},{"key":"887_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrclinonc.2014.42","volume":"11","author":"JA Burger","year":"2014","unstructured":"Burger, J. A. & Okkenhaug, K. Idelalisib\u2014targeting PI3K\u03b4 in patients with B-cell malignancies. Nat. Rev. Clin. Oncol. 11, 184\u2013186 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"887_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","volume":"20","author":"G Petroni","year":"2020","unstructured":"Petroni, G., Formenti, S. C., Chen-Kiang, S. & Galluzzi, L. Immunomodulation by anticancer cell cycle inhibitors. Nat. Rev. Immunol. 20, 669\u2013679 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"887_CR30","doi-asserted-by":"publisher","first-page":"875372","DOI":"10.3389\/fphar.2022.875372","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu, X. et al. Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment. Front. Pharmacol. 13, 875372 (2022).","journal-title":"Front. Pharmacol."},{"key":"887_CR31","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah, N. P. et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J. Clin. Investigat. 117, 2562\u20132569 (2007).","journal-title":"J. Clin. Investigat."},{"key":"887_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/nrd2130","volume":"5","author":"S Wilhelm","year":"2006","unstructured":"Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5, 835\u2013844 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"887_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. Kegg: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"887_CR34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","volume":"395","author":"F Paech","year":"2018","unstructured":"Paech, F. et al. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. Toxicology 395, 34\u201344 (2018).","journal-title":"Toxicology"},{"key":"887_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12519-4","volume":"12","author":"F Ek","year":"2022","unstructured":"Ek, F. et al. Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma. Sci. Rep. 12, 8943 (2022).","journal-title":"Sci. Rep."},{"key":"887_CR36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/leu.2011.360","volume":"26","author":"E Weisberg","year":"2012","unstructured":"Weisberg, E. et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985\u2013990 (2012).","journal-title":"Leukemia"},{"key":"887_CR37","unstructured":"Sorafenib Completed Phase 2 Trials for Chronic Myelogenous Leukemia (CML) Treatment (DrugBank, accessed 3 August 2025); https:\/\/go.drugbank.com\/drugs\/DB00398\/clinical_trials?conditions=DBCOND0040386&phase=2&purpose=treatment&status=completed"},{"key":"887_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/neuonc\/nou350","volume":"17","author":"EQ Lee","year":"2015","unstructured":"Lee, E. Q. et al. Phase ii study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro-oncology 17, 862\u2013867 (2015).","journal-title":"Neuro-oncology"},{"key":"887_CR39","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1073\/pnas.0508500103","volume":"103","author":"S Xiong","year":"2006","unstructured":"Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G. & Lozano, G. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc. Natl Acad. Sci. USA 103, 3226\u20133231 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"887_CR40","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","volume":"34","author":"M Konopleva","year":"2020","unstructured":"Konopleva, M. et al. MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34, 2858\u20132874 (2020).","journal-title":"Leukemia"},{"key":"887_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrc1887","volume":"6","author":"CD Scripture","year":"2006","unstructured":"Scripture, C. D. & Figg, W. D. Drug interactions in cancer therapy. Nat. Rev. Cancer 6, 546\u2013558 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"887_CR42","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41592-023-02040-5","volume":"20","author":"M Dong","year":"2023","unstructured":"Dong, M. et al. Causal identification of single-cell experimental perturbation effects with CINEMA-OT. Nat. Methods 20, 1769\u20131779 (2023).","journal-title":"Nat. Methods"},{"key":"887_CR43","unstructured":"Landrum, G. et al. RDKit: Open-Source Cheminformatics Software (RDKit, 2016)."},{"key":"887_CR44","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox, C. et al. Drugbank 6.0: the drugbank knowledgebase for 2024. Nucleic Acids Res. 52, D1265\u2013D1275 (2024).","journal-title":"Nucleic Acids Res."},{"key":"887_CR45","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Pubchem 2023 update. Nucleic Acids Res. 51, D1373\u2013D1380 (2023).","journal-title":"Nucleic Acids Res."},{"key":"887_CR46","doi-asserted-by":"publisher","first-page":"D431","DOI":"10.1093\/nar\/gkz1023","volume":"48","author":"V Stathias","year":"2020","unstructured":"Stathias, V. et al. Lincs data portal 2.0: next generation access point for perturbation-response signatures. Nucleic Acids Res. 48, D431\u2013D439 (2020).","journal-title":"Nucleic Acids Res."},{"key":"887_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00894-y","volume":"13","author":"W Zhao","year":"2021","unstructured":"Zhao, W. et al. Deconvolution of cell type-specific drug responses in human tumor tissue with single-cell RNA-seq. Genome Med. 13, 82 (2021).","journal-title":"Genome Med."},{"key":"887_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21884-z","volume":"12","author":"AF Aissa","year":"2021","unstructured":"Aissa, A. F. et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nat. Commun. 12, 1628 (2021).","journal-title":"Nat. Commun."},{"key":"887_CR49","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41587-020-0465-8","volume":"38","author":"J Ding","year":"2020","unstructured":"Ding, J. et al. Systematic comparison of single-cell and single-nucleus RNA-sequencing methods. Nat. Biotechnol. 38, 737\u2013746 (2020).","journal-title":"Nat. Biotechnol."},{"key":"887_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol,.19, 15 (2018).","journal-title":"Genome Biol,."},{"key":"887_CR51","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen, P. et al. Scipy 1.0: fundamental algorithms for scientific computing in Python. Nat. Methods 17, 261\u2013272 (2020).","journal-title":"Nat. Methods"},{"key":"887_CR52","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.21105\/joss.04101","volume":"7","author":"NickiSkafte Detlefsen","year":"2022","unstructured":"Detlefsen, NickiSkafte et al. TorchMetrics-measuring reproducibility in PyTorch. J. Open Source Softw. 7, 4101 (2022).","journal-title":"J. Open Source Softw."},{"key":"887_CR53","unstructured":"Feydy, J. et al. Interpolating between optimal transport and MMD using sinkhorn divergences. In Proc. 22nd International Conference on Artificial Intelligence and Statistics 2681\u20132690 (PMLR, 2019)."},{"key":"887_CR54","unstructured":"Cuturi, M. Sinkhorn distances: lightspeed computation of optimal transport. In Proc. Advances in Neural Information Processing Systems Vol. 26 (NIPS, 2013)."},{"key":"887_CR55","doi-asserted-by":"publisher","first-page":"btac757","DOI":"10.1093\/bioinformatics\/btac757","volume":"39","author":"Z Fang","year":"2023","unstructured":"Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 (2023).","journal-title":"Bioinformatics"},{"key":"887_CR56","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Predicting drug responses of unseen cell types through transfer learning with foundation models. Zenodo https:\/\/doi.org\/10.5281\/zenodo.16713259 (2025).","DOI":"10.5281\/zenodo.16713259"},{"key":"887_CR57","doi-asserted-by":"publisher","first-page":"7514","DOI":"10.1200\/jco.2011.29.15_suppl.7514","volume":"29","author":"L Crino","year":"2011","unstructured":"Crino, L. et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): profile 1005. J. Clin. Oncol. 29, 7514 (2011).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Computational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43588-025-00887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43588-025-00887-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43588-025-00887-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:03:59Z","timestamp":1769691839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43588-025-00887-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1038\/s43588-025-00887-6","relation":{},"ISSN":["2662-8457"],"issn-type":[{"value":"2662-8457","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}